167 related articles for article (PubMed ID: 10160470)
1. Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis.
Payne K; Kozma CM; Lawrence BJ
Pharmacoeconomics; 1996 Jul; 10(1):59-71. PubMed ID: 10160470
[TBL] [Abstract][Full Text] [Related]
2. A literature review comparing the economic, clinical, and humanistic attributes of dihydroergotamine and sumatriptan.
Kozma CM; Mauch RP; Reeder CE; Lawrence BJ
Clin Ther; 1994; 16(6):1037-51; discussion 1036. PubMed ID: 7697683
[TBL] [Abstract][Full Text] [Related]
3. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine.
Boureau F; Kappos L; Schoenen J; Esperanca P; Ashford E
Int J Clin Pract; 2000 Jun; 54(5):281-6. PubMed ID: 10954953
[TBL] [Abstract][Full Text] [Related]
4. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.
Winner P; Ricalde O; Le Force B; Saper J; Margul B
Arch Neurol; 1996 Feb; 53(2):180-4. PubMed ID: 8639069
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation.
Laloux P; Vakaet A; Monseu G; Jacquy J; Bourgeois P; van der Linden C
Acta Neurol Belg; 1998 Dec; 98(4):332-41. PubMed ID: 9922821
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine.
Zhang L; Hay JW
CNS Drugs; 2005; 19(7):635-42. PubMed ID: 15984898
[TBL] [Abstract][Full Text] [Related]
7. Sumatriptan. An updated review of its use in migraine.
Perry CM; Markham A
Drugs; 1998 Jun; 55(6):889-922. PubMed ID: 9617601
[TBL] [Abstract][Full Text] [Related]
8. Sumatriptan. A pharmacoeconomic review of its use in migraine.
Coukell AJ; Lamb HM
Pharmacoeconomics; 1997 May; 11(5):473-90. PubMed ID: 10168035
[TBL] [Abstract][Full Text] [Related]
9. Sumatriptan and migraine.
Akpunonu BE; Mutgi AB
Ann Emerg Med; 1996 Mar; 27(3):387-8. PubMed ID: 8599506
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine.
Lofland JH; Kim SS; Batenhorst AS; Johnson NE; Chatterton ML; Cady RK; Kaniecki R; Nash DB
Mayo Clin Proc; 2001 Nov; 76(11):1093-101. PubMed ID: 11702897
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the economic, clinical, and humanistic attributes of dihydroergotamine and sumatriptan.
Kozma CM; Reeder CE
Clin Ther; 1995; 17(2):315-9; discussion 314. PubMed ID: 7614531
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of sumatriptan in a managed care population.
Legg RF; Sclar DA; Nemec NL; Tarnai J; Mackowiak JI
Am J Manag Care; 1997 Jan; 3(1):117-22. PubMed ID: 10169243
[TBL] [Abstract][Full Text] [Related]
13. Economic implications of early treatment of migraine with sumatriptan tablets.
Cady RK; Sheftell F; Lipton RB; Kwong WJ; O'Quinn S
Clin Ther; 2001 Feb; 23(2):284-91. PubMed ID: 11293561
[TBL] [Abstract][Full Text] [Related]
14. Reduced efficacy of sumatriptan in migraine with aura vs without aura.
Hansen JM; Goadsby PJ; Charles A
Neurology; 2015 May; 84(18):1880-5. PubMed ID: 25841032
[TBL] [Abstract][Full Text] [Related]
15. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine.
Touchon J; Bertin L; Pilgrim AJ; Ashford E; Bès A
Neurology; 1996 Aug; 47(2):361-5. PubMed ID: 8757005
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray.
Hoffman L; Mayzell G; Pedan A; Farrell M; Gilbert T
J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452
[TBL] [Abstract][Full Text] [Related]
17. Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis.
Caro G; Getsios D; Caro JJ; Raggio G; Burrows M; Black L
Cephalalgia; 2001 Feb; 21(1):12-9. PubMed ID: 11298658
[TBL] [Abstract][Full Text] [Related]
18. Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies.
Tfelt-Hansen P
Cephalalgia; 2000 Mar; 20(2):137. PubMed ID: 10961773
[No Abstract] [Full Text] [Related]
19. Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan.
Wang JT; Barr CE; Goldfarb SD
Headache; 2002 Jan; 42 Suppl 1():38-43. PubMed ID: 11966863
[TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine.
Wells N; Hettiarachchi J; Drummond M; DPhil M; Carter D; Parpia T; Pang F
Value Health; 2003; 6(4):438-47. PubMed ID: 12859585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
